Our findings are consistent with the current consensus that Lp(a) amplifies the increased risk of ASCVD that is already present among individuals with genetic hypercholesterolemia and that these individuals must have their Lp(a) determined as part of comprehensive risk assessment. The gene discussed is LPA; the disease is atherosclerosis.